Fig. 1From: Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfaFlow of patients in the HALO 109-202 plasma biomarker analysisBack to article page